27-hydroxycholesterol has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, AE; Burdette, JE; Chen, JJ; He, S; Ma, L; Nelson, AT; Nelson, ER; Vardanyan, A; Vembar, V | 1 |
| Juberiya, AM; Sreeja, S; Vini, R | 1 |
2 other study(ies) available for 27-hydroxycholesterol and Cancer of Ovary
| Article | Year |
|---|---|
Host CYP27A1 expression is essential for ovarian cancer progression.
Topics: Animals; B7-H1 Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cholestanetriol 26-Monooxygenase; Cholesterol, Dietary; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Hydroxycholesterols; Mice; Myeloid-Derived Suppressor Cells; Ovarian Neoplasms; Prognosis; Progression-Free Survival; Xenograft Model Antitumor Assays | 2019 |
Evidence of pomegranate methanolic extract in antagonizing the endogenous SERM, 27-hydroxycholesterol.
Topics: Animals; Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Humans; Hydroxycholesterols; Lythraceae; MCF-7 Cells; Mice; Obesity; Ovarian Neoplasms; Plant Extracts; Uterine Cervical Neoplasms | 2016 |